Cancer Care at Saint Clare's Now Offers Xifigo® for Prostate Cancer
Facility is first in Morris County to offer FDA-approved radioactive therapeutic
drug for advanced metastatic prostate cancer
DENVILLE, NJ – September 19, 2013 – Cancer Care at Saint Clare’s, the comprehensive oncology program for Saint Clare’s Health System,
now offers Xofigo® , which is the first alpha particle-emitting radioactive
therapeutic agent approved by the Food and Drug Administration (FDA).
The injection is available for treatment of patients with castration-resistant
prostate cancer (CRPC), symptomatic bone metastases and no known visceral
Cancer Care at Saint Clare’s is the first facility in Morris County to offer this treatment option.
Bone is the most common site in the body to be affected by metastatic cancer,
and bone metastases are particularly prevalent in patients with prostate
cancer. Approximately 90 percent of patients with metastatic prostate
cancer show evidence of bone metastases, which is the main cause of death
in patients with prostate cancer.
"This injection offers a treatment opportunity for patients with castration-resistant
prostate cancer with metastatic bone disease who have failed hormone suppression
therapy," said Donald Cann, MD, medical director of radiation oncology at
Cancer Care at Saint Clare’s in Denville. "This Radium Ra 223 injection mimics the behavior of
calcium, and the subsequent high linear energy transfer of Xofigo®
may actually result in an anti-tumor effect on the bone, -- which kills
the cancer and allows the bone to recover.”
Experts say Xofigo® is the first and only alpha particle-emitting radioactive
therapeutic agent approved by the FDA that has demonstrated improvement
in overall survival rates. The drug's anti-tumor effect on bone metastases
is an important addition to the treatment of this cancer.
Patients who receive radium RA 223 dichloride injections pose no harm to
others around them, despite the agent being radioactive. Most insurance
companies cover the treatment, which is tolerated well.
As a Commission on Cancer-accredited cancer center,
Cancer Care at Saint Clare’s takes a multidisciplinary approach to treating cancer as a complex group
of diseases that requires consultation among surgeons, medical and radiation
oncologists, diagnostic radiologists, pathologists, and other cancer specialists.
This multidisciplinary partnership results in improved patient care.
Algeta is a company focused on developing novel targeted therapies for
patients with cancer based on its alpha-pharmaceutical platform. The Company
is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US,
LLC, based in Cambridge, MA performing commercial marketing operations
in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA).
For more information please visit